Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its target price lifted by investment analysts at Cantor Fitzgerald from $11.00 to $19.00 in a research report issued on Thursday, Marketbeat Ratings reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 117.14% from the company’s previous close.

EPRX has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Eupraxia Pharmaceuticals in a report on Friday, January 9th. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Wall Street Zen raised Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, October 8th. Finally, Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $14.33.

Eupraxia Pharmaceuticals Stock Down 0.2%

NASDAQ EPRX opened at $8.75 on Thursday. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $8.89. The business’s fifty day simple moving average is $6.86 and its 200-day simple moving average is $6.00. The firm has a market cap of $314.65 million, a PE ratio of -10.06 and a beta of 1.21.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Research analysts expect that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

Several hedge funds have recently made changes to their positions in EPRX. Quadrature Capital Ltd purchased a new position in shares of Eupraxia Pharmaceuticals in the second quarter valued at approximately $61,000. TCI Wealth Advisors Inc. acquired a new stake in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $65,000. Integrated Wealth Concepts LLC purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $71,000. Bank of America Corp DE grew its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Eupraxia Pharmaceuticals by 593.2% during the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after acquiring an additional 16,017 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.